Bexion Pharmaceuticals
Clinical‑stage biopharmaceutical company developing a first‑in‑class biologic that modulates sphingolipid metabolism to target tumor survival pathways and treatment resistance. The lead investigational program is a protein‑based nanovesicle biologic intended for use alone and in combination with standard oncology regimens; programs include adult and pediatric oncology trials and translational biomarker development.
Industries
Nr. of Employees
small (1-50)
Bexion Pharmaceuticals
Patents
Products
Investigational sphingolipid‑modulating biologic (lead program)
An investigational protein‑based nanovesicle biologic designed to modulate sphingolipid metabolism (lower sphingosine‑1‑phosphate and increase ceramides) to produce direct anti‑tumor effects and potential neuroprotective benefits; available only to clinical trial participants.
BXQ-350
BXQ-350 is an investigational therapeutic evaluated in clinical trials for advanced solid tumors, metastatic colorectal carcinoma, pediatric brain tumors, and diffuse midline glioma.
Investigational sphingolipid‑modulating biologic (lead program)
An investigational protein‑based nanovesicle biologic designed to modulate sphingolipid metabolism (lower sphingosine‑1‑phosphate and increase ceramides) to produce direct anti‑tumor effects and potential neuroprotective benefits; available only to clinical trial participants.
BXQ-350
BXQ-350 is an investigational therapeutic evaluated in clinical trials for advanced solid tumors, metastatic colorectal carcinoma, pediatric brain tumors, and diffuse midline glioma.
Services
Sponsorship and operational management of clinical development programs for a protein‑based nanovesicle biologic across Phase 1 to randomized Phase 2 oncology studies, including pediatric programs and translational biomarker components.
Sponsorship and operational management of clinical development programs for a protein‑based nanovesicle biologic across Phase 1 to randomized Phase 2 oncology studies, including pediatric programs and translational biomarker components.
Expertise Areas
- Clinical trial management (oncology, adult and pediatric)
- Biomarker development and translational medicine
- Preclinical pharmacology and disease modeling
- Nanovesicle biologic formulation
Key Technologies
- Nanovesicle formulation for protein biologics
- Protein activator‑based biologics
- Lipidomics (S1P and ceramide quantification)
- PK/PD analysis
News & Updates
Multiple poster presentations and abstracts reported for ASCO, AACR, SITC and other conferences describing preclinical and clinical data.
Multiple poster presentations and abstracts reported for ASCO, AACR, SITC and other conferences describing preclinical and clinical data.